Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
활용도 Analysis
논문 Analysis
연구자 Analysis
저자
최재영
고재성
최병호
김정은
강빈
이경재
양혜란
제어번호
104771664
학술지명
Journal of Korean medical science
권호사항
Vol.
33
No.
2
[
2018
]
발행처
대한의학회
자료유형
학술저널
수록면
24-33
언어
English
출판년도
2018
등재정보
KCI등재
판매처
'
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B' 의 참고문헌
What physicians should know about the management of chronic hepatitis B in children: east side story
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B
Treatment outcomes with first-line therapies with entecavir and tenofovir in treatment-naive chronic hepatitis b patients in a routine clinical practice
Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses
Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B
Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B
Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea
Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting
Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection
Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
Efficacy and safety of tenofovir in nucleos(t)ide-naive patients with genotype C chronic hepatitis B in real-life practice
Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis b: a 3-year, prospective, real-world study in France
Effect of long-term lamivudine in chronic hepatitis B virus-infected children
EASL clinical practice guidelines: management of chronic hepatitis B virus infection
Combination of tenofovir disoproxil fumarate and peginterferon <TEX>${\alpha}$</TEX>-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B
Chronic hepatitis B: update 2009
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
'
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B'
의 유사주제(
